Congress creates private lawsuits to enforce abortion disclosure rules

What it does

This bill requires doctors who perform medication abortions and receive federal funding to provide women with FDA-approved drug labels highlighting warnings and side effects, read those sections aloud, and obtain written confirmation at least 24 hours before the procedure. It allows women to sue providers for violations, claiming actual damages, triple the abortion cost, punitive damages, and attorney fees. The bill defines 'chemical abortion' narrowly to exclude treatment of miscarriage, ectopic pregnancy, and cases where abortion prevents the mother's death or serious bodily harm.

Why we flagged it

The bill's operative mechanism is a mandatory disclosure and informed-consent requirement paired with a private right of action. While framed as 'risk awareness,' the 24-hour waiting period, written confirmation requirement, and triple-damages liability structure function as procedural barriers to abortion access, not merely informational measures.

What the text implies

• The 24-hour waiting period may be unenforceable in states without their own waiting-period laws, creating a patchwork of compliance obligations that varies by state and federal funding source.
• The private right of action creates incentive for litigation against providers even for technical violations (e.g., failure to highlight specific label sections), potentially chilling provision of medication abortion regardless of actual harm.
• The definition of 'woman' as 'a human being with XX chromosomes' may conflict with state law definitions and create ambiguity for transgender and intersex patients seeking abortion care.
• Triple damages and punitive damages provisions may expose providers to liability far exceeding actual harm, functioning as a de facto penalty on abortion provision beyond the stated disclosure requirement.
• The bill applies only to federally-funded providers, creating incentive for private practices to decline federal funding to avoid compliance, potentially fragmenting abortion access along funding lines.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a concrete procedural barrier to abortion access (24-hour delay, mandatory disclosure, written confirmation) that may deter or delay some women seeking medication abortion, particularly those with limited time or resources. However, the informed-consent mechanism itself—providing FDA-approved safety information—is a legitimate disclosure practice in medical care, and the private right of action gives women a legal remedy if providers fail to comply. The balance between procedura

Who stands to gain

• plaintiff's attorneys (attorney fee awards)
• litigation funders targeting abortion providers

Named in the bill

FDA, Secretary of Health and Human Services, chemical abortion providers, federally-funded medical practices

Where it stands

2 cosponsors: 2 Republicans.

• Jan 23, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jan 23, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.